New antibody therapy shows promising results for advanced, treatment-refractory pediatric brain cancer
Effective and safe treatments are needed for medulloblastoma—the most common type of cancerous brain tumor in children—especially for patients whose cancer has spread to the spinal cord. A recent phase I clinical trial led by researchers at Atrium Health Levine Children’s Hospital and Massachusetts General Hospital (MGH) has generated promising…...
A Closer Look at Glioblastoma and New Reasons for Hope
Approximately 15,000 Americans will be diagnosed with glioblastoma this year. Although considered a rare cancer, doctors are seeing an increase in cases of the aggressive and deadly brain cancer that’s notoriously hard to treat. A local organization that’s helping enroll brain cancer patients in clinical trials around the world gives…...
Using rooom to Build a Community
Together with the National Foundation for Cancer Research (NFCR) and the AIM-HI Accelerator Fund (AIM-HI) we hosted a charitable hybrid combo event on October 30 2021 – our first big project in the United States. While the live event took place at the National Press Club in Washington, D.C., virtual participation was…...
NFCR CMO Brian Leyland-Jones Featured in Pancreatic Cancer Risk Overview
Insights from National Foundation for Cancer Research Chief Medical Officer Brian Leyland-Jones, along with such other authoritative sources as Johns Hopkins Medicine, the Mayo Clinic and the U.S. National Cancer Institute, are featured in this Eat This, Not That! overview of pancreatic cancer warning signs....
Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, To Receive Inaugural AACR Scientific Achievement Award Established in His Honor
PHILADELPHIA – The American Association for Cancer Research (AACR) announced today that Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, will receive the inaugural AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research. Von Hoff is being recognized for his groundbreaking accomplishments as…...
- 1
- 2